Evidence map›Paper›PMID 42488857›Full record

ReviewNigerian medical journal : journal of the Nigeria Medical Association

Marburg Virus: A Looming Threat Nigeria Cannot Ignore.

Emmanuel O Oisakede

Abstract readReview
In one paragraph

Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emmanuel O OisakedeDepartment of Clinical Oncology, Leeds Teaching Hospitals Trust, Leeds, England.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To the Editor: Marburg virus, a filovirus closely related to Ebola, causes a severe haemorrhagic illness with case fatality rates ranging from 24 % to 88 %, depending on the timeliness and strength of the outbreak response [1]. Transmission occurs through contact with infected body fluids or contaminated materials, and via exposure to infected fruit bats ( Proposed Model for Reducing MVD and other VHF Transmission: Currently, no licensed vaccine exists for the Marburg virus or other VHFs, although several candidates are in preclinical or early-phase trials. However, vaccine development may take several years before wide deployment. To mitigate transmission and reduce disease impact, we propose a four-tiered model that can function even in the absence of a vaccine, focusing on environmental, ecological, and health system interventions.This Oisakede's Inverted Triangular Model (Fig. 1) outlines a sequential, evidence-based approach:i.Safe Built Environment: Promote environmental hygiene and structural designs that minimise human contact with vectors or reservoirs (e.g., fruit bats).ii.Eliminate or Drive Out the Culprit: Target vector control and wildlife surveillance to limit zoonotic spillover.iii.Provide Timely Treatment: Ensure rapid diagnosis, case management, and IPC compliance to prevent nosocomial transmission.iv.Vaccination (When Available): Once safe and effective vaccines become available, immunisation programmes should prioritise high-risk communities.The model is initially inverted, representing the current phase where prevention and surveillance dominate due to a lack of vaccines. Once vaccines are available, the triangle can be flipped upright, symbolising a shift toward immunity-based protection for high-risk populations under

Identifiers

PMID42488857
PMCPMC13391109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.